Previous 10 | Next 10 |
Gritstone Oncology (NASDAQ: GRTS ): Q4 GAAP EPS of -$0.77 misses by $0.04 . More news on: Gritstone Oncology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
EMERYVILLE, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the fourth quarter and full ye...
EMERYVILLE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president ...
The following slide deck was published by Gritstone Oncology, Inc. in conjunction with this Read more ...
Gainers: RTI Surgical RTIX +66% . More news on: IRIDEX Corporation, Inpixon, Gritstone Oncology, Inc., Stocks on the move, , Read more ...
EMERYVILLE, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president ...
Gainers: Amneal Pharmaceuticals (NYSE: AMRX ) +49% . More news on: Amneal Pharmaceuticals, Inc., Diebold Nixdorf, Incorporated, Assembly Biosciences, Inc., Stocks on the move, Read more ...
Thinly traded micro cap Gritstone Oncology ( GRTS -14.6% ) slumps on modestly higher volume in early trade on the heels of preliminary data from early-stages studies evaluating lead candidate GRANITE and candidate #2 SLATE. The results, apparently disappointing investors, were presented ...
- - Preliminary results demonstrate unprecedented levels of primed CD8+ neoantigen-specific cytotoxic T cells and expansion of pre-existing T cells even in low-dose cohorts -- -- Investor conference call and webcast at 8:00 am ET today -- EMERYVILLE, Calif., Dec. 12, 2019 (GLOBE NEW...
EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the executive management team will webcast a revi...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...